<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="UTF-8">
  <meta name="viewport" content="width=device-width, initial-scale=1.0">
  <title>Medical Research NDA | Clinical Trials & Research Partnerships | Terms.Law</title>
  <meta name="description" content="NDA templates for clinical trials, medical research partnerships, and academic collaborations. Includes IRB considerations, de-identification requirements, publication rights, and FDA submission provisions.">
  <link rel="canonical" href="https://terms.law/NDA/industry-packs/healthcare/medical-research-nda.html">

  <script type="application/ld+json">
  {"@context":"https://schema.org","@type":"FAQPage","mainEntity":[
  {"@type":"Question","name":"What special provisions do clinical trial NDAs need?","acceptedAnswer":{"@type":"Answer","text":"Clinical trial NDAs require provisions for: IRB (Institutional Review Board) oversight compliance, patient data de-identification per HIPAA Safe Harbor or Expert Determination methods, publication rights and timing restrictions, adverse event reporting obligations, FDA submission rights, and sponsor vs. investigator data ownership."}},
  {"@type":"Question","name":"How do publication rights work in medical research NDAs?","acceptedAnswer":{"@type":"Answer","text":"Publication rights typically include: a review period (30-90 days) before submission, the right to delay publication to file patents, restrictions on publishing proprietary methods or trade secrets, and acknowledgment requirements. Academic institutions often negotiate for guaranteed publication rights."}},
  {"@type":"Question","name":"What is the minimum data de-identification requirement for research NDAs?","acceptedAnswer":{"@type":"Answer","text":"HIPAA provides two de-identification methods: Safe Harbor (removing 18 specific identifiers) and Expert Determination (statistical certification that re-identification risk is very small). Research NDAs should specify which method applies and who bears de-identification responsibility."}},
  {"@type":"Question","name":"Who owns clinical trial data under a research NDA?","acceptedAnswer":{"@type":"Answer","text":"Data ownership varies by arrangement: Sponsors typically own raw trial data and results. Investigators may retain rights to publish and use aggregated findings. Academic institutions often negotiate joint ownership or perpetual license rights. The NDA should clearly define ownership, usage rights, and regulatory submission authority."}}
  ]}
  </script>

  <!-- Google Analytics -->
  <script async src="https://www.googletagmanager.com/gtag/js?id=G-901N2Y3CDZ"></script>
  <script>
    window.dataLayer = window.dataLayer || [];
    function gtag(){dataLayer.push(arguments);}
    gtag('js', new Date());
    gtag('config', 'G-901N2Y3CDZ');
  </script>

  <link rel="preconnect" href="https://fonts.googleapis.com">
  <link href="https://fonts.googleapis.com/css2?family=Inter:wght@400;500;600;700;800&display=swap" rel="stylesheet">
  <style>
    :root {
      --primary: #2563eb;
      --primary-dark: #1d4ed8;
      --accent: #8b5cf6;
      --success: #10b981;
      --warning: #f59e0b;
      --danger: #ef4444;
      --healthcare: #0891b2;
      --healthcare-dark: #0e7490;
      --healthcare-light: #ecfeff;
      --research: #7c3aed;
      --research-light: #f5f3ff;
      --dark: #0f172a;
      --dark-lighter: #1e293b;
      --gray-50: #f8fafc;
      --gray-100: #f1f5f9;
      --gray-200: #e2e8f0;
      --gray-300: #cbd5e1;
      --gray-400: #94a3b8;
      --gray-500: #64748b;
      --gray-600: #475569;
      --gray-700: #334155;
      --gray-800: #1e293b;
    }

    * { box-sizing: border-box; margin: 0; padding: 0; }
    html { scroll-behavior: smooth; }
    body {
      font-family: 'Inter', -apple-system, BlinkMacSystemFont, sans-serif;
      background: var(--gray-50);
      color: var(--gray-700);
      line-height: 1.6;
    }

    /* Header Styles */
    .site-header {
        background: linear-gradient(135deg, #0f172a 0%, #1e293b 100%);
        position: sticky;
        top: 0;
        z-index: 1000;
        box-shadow: 0 4px 20px rgba(0,0,0,0.3);
    }
    .header-content {
        max-width: 1400px;
        margin: 0 auto;
        display: flex;
        align-items: center;
        padding: 0 24px;
        height: 60px;
    }
    .site-logo {
        font-size: 1.15rem;
        font-weight: 800;
        text-decoration: none;
        background: linear-gradient(135deg, #60a5fa 0%, #a78bfa 100%);
        -webkit-background-clip: text;
        -webkit-text-fill-color: transparent;
        margin-right: 32px;
    }
    .site-nav {
        display: flex;
        align-items: center;
        gap: 0;
        flex: 1;
    }
    .nav-link {
        padding: 18px 16px;
        color: #94a3b8;
        text-decoration: none;
        font-size: 14px;
        font-weight: 500;
        transition: all 0.2s;
    }
    .nav-link:hover { color: #fff; }
    .nav-cta {
        margin-left: auto;
        background: linear-gradient(135deg, #2563eb 0%, #7c3aed 100%);
        color: #fff !important;
        padding: 10px 20px !important;
        border-radius: 8px;
        font-weight: 600 !important;
    }

    /* Hub Sub-Navigation */
    .hub-subnav {
      background: linear-gradient(135deg, #0e7490 0%, #0891b2 100%);
    }
    .hub-subnav-content {
      max-width: 1400px;
      margin: 0 auto;
      padding: 0 24px;
      display: flex;
      align-items: center;
      justify-content: space-between;
      height: 48px;
    }
    .hub-subnav-title {
      color: #fff;
      font-size: 0.9rem;
      font-weight: 700;
      text-decoration: none;
    }
    .hub-subnav-tabs { display: flex; gap: 8px; }
    .hub-tab {
      padding: 8px 16px;
      color: rgba(255,255,255,0.8);
      text-decoration: none;
      font-size: 0.85rem;
      font-weight: 500;
      border-radius: 6px;
      transition: all 0.2s;
    }
    .hub-tab:hover { background: rgba(255,255,255,0.15); color: #fff; }
    .hub-tab.active { background: rgba(255,255,255,0.2); color: #fff; }

    /* Hero */
    .hero {
      background: linear-gradient(135deg, #5b21b6 0%, #7c3aed 50%, #8b5cf6 100%);
      padding: 3rem 2rem;
    }
    .hero-inner {
      max-width: 900px;
      margin: 0 auto;
      text-align: center;
    }
    .hero-badge {
      display: inline-flex;
      align-items: center;
      gap: 8px;
      background: rgba(255,255,255,0.15);
      border: 1px solid rgba(255,255,255,0.3);
      padding: 6px 16px;
      border-radius: 100px;
      font-size: 0.8rem;
      color: #fff;
      margin-bottom: 1.5rem;
    }
    .hero h1 {
      font-size: 2.5rem;
      font-weight: 800;
      color: white;
      margin-bottom: 1rem;
    }
    .hero-sub {
      font-size: 1.1rem;
      color: rgba(255,255,255,0.9);
      max-width: 650px;
      margin: 0 auto;
    }

    /* Main Content */
    .main-content {
      max-width: 1200px;
      margin: 0 auto;
      padding: 3rem 2rem;
    }

    /* Research Types */
    .research-types {
      display: grid;
      grid-template-columns: repeat(3, 1fr);
      gap: 1.5rem;
      margin-bottom: 3rem;
    }
    @media (max-width: 900px) { .research-types { grid-template-columns: 1fr; } }
    .research-type-card {
      background: white;
      border: 2px solid var(--gray-200);
      border-radius: 16px;
      padding: 1.5rem;
      transition: all 0.3s;
    }
    .research-type-card:hover {
      border-color: var(--research);
      transform: translateY(-4px);
    }
    .research-type-icon {
      font-size: 2rem;
      margin-bottom: 1rem;
    }
    .research-type-card h3 {
      font-size: 1.1rem;
      font-weight: 700;
      color: var(--dark);
      margin-bottom: 0.5rem;
    }
    .research-type-card p {
      font-size: 0.9rem;
      color: var(--gray-600);
    }

    /* Section Styles */
    .section { margin-bottom: 3rem; }
    .section h2 {
      font-size: 1.75rem;
      font-weight: 800;
      color: var(--dark);
      margin-bottom: 1.5rem;
      display: flex;
      align-items: center;
      gap: 12px;
    }

    /* IRB Section */
    .irb-section {
      background: var(--research-light);
      border: 2px solid #c4b5fd;
      border-radius: 16px;
      padding: 2rem;
      margin-bottom: 3rem;
    }
    .irb-section h2 { color: #5b21b6; }
    .irb-considerations {
      display: grid;
      grid-template-columns: repeat(2, 1fr);
      gap: 1rem;
      margin-top: 1.5rem;
    }
    @media (max-width: 768px) { .irb-considerations { grid-template-columns: 1fr; } }
    .irb-item {
      background: white;
      border-radius: 10px;
      padding: 1rem;
      display: flex;
      align-items: flex-start;
      gap: 12px;
    }
    .irb-item-icon {
      font-size: 1.25rem;
      flex-shrink: 0;
    }
    .irb-item h4 {
      font-size: 0.95rem;
      font-weight: 600;
      color: var(--dark);
      margin-bottom: 0.25rem;
    }
    .irb-item p {
      font-size: 0.85rem;
      color: var(--gray-600);
    }

    /* De-identification Methods */
    .deid-section {
      background: white;
      border: 2px solid var(--gray-200);
      border-radius: 16px;
      padding: 2rem;
      margin-bottom: 3rem;
    }
    .deid-methods {
      display: grid;
      grid-template-columns: 1fr 1fr;
      gap: 1.5rem;
      margin-top: 1.5rem;
    }
    @media (max-width: 768px) { .deid-methods { grid-template-columns: 1fr; } }
    .deid-method {
      border: 2px solid var(--gray-200);
      border-radius: 12px;
      padding: 1.5rem;
    }
    .deid-method.preferred { border-color: var(--success); background: #f0fdf4; }
    .deid-method h4 {
      font-size: 1.1rem;
      font-weight: 700;
      color: var(--dark);
      margin-bottom: 0.5rem;
    }
    .deid-method .tag {
      display: inline-block;
      padding: 2px 8px;
      border-radius: 4px;
      font-size: 0.7rem;
      font-weight: 600;
      margin-bottom: 0.75rem;
    }
    .tag-preferred { background: #dcfce7; color: #166534; }
    .tag-alternative { background: #fef3c7; color: #92400e; }
    .deid-method p {
      font-size: 0.9rem;
      color: var(--gray-600);
      margin-bottom: 1rem;
    }
    .identifiers-list {
      font-size: 0.8rem;
      color: var(--gray-500);
      margin-left: 1.25rem;
    }
    .identifiers-list li { margin-bottom: 0.25rem; }

    /* Publication Rights */
    .publication-section {
      background: #fffbeb;
      border: 2px solid #fcd34d;
      border-radius: 16px;
      padding: 2rem;
      margin-bottom: 3rem;
    }
    .publication-section h2 { color: #92400e; }
    .publication-timeline {
      display: flex;
      align-items: center;
      justify-content: space-between;
      margin: 2rem 0;
      position: relative;
    }
    .publication-timeline::before {
      content: '';
      position: absolute;
      top: 20px;
      left: 60px;
      right: 60px;
      height: 4px;
      background: #fcd34d;
    }
    .timeline-point {
      text-align: center;
      position: relative;
      z-index: 1;
    }
    .timeline-dot {
      width: 40px;
      height: 40px;
      background: #f59e0b;
      border-radius: 50%;
      display: flex;
      align-items: center;
      justify-content: center;
      color: white;
      font-weight: 700;
      font-size: 0.9rem;
      margin: 0 auto 0.5rem;
    }
    .timeline-label {
      font-size: 0.75rem;
      color: var(--gray-600);
      max-width: 100px;
    }
    @media (max-width: 768px) {
      .publication-timeline { flex-direction: column; gap: 1.5rem; }
      .publication-timeline::before { display: none; }
    }

    /* FDA Section */
    .fda-section {
      background: white;
      border: 2px solid var(--gray-200);
      border-radius: 16px;
      padding: 2rem;
      margin-bottom: 3rem;
    }
    .fda-rights {
      display: grid;
      grid-template-columns: repeat(2, 1fr);
      gap: 1rem;
      margin-top: 1.5rem;
    }
    @media (max-width: 768px) { .fda-rights { grid-template-columns: 1fr; } }
    .fda-right {
      background: var(--gray-50);
      border-radius: 10px;
      padding: 1rem;
    }
    .fda-right h4 {
      font-size: 0.95rem;
      font-weight: 600;
      color: var(--dark);
      margin-bottom: 0.25rem;
    }
    .fda-right p {
      font-size: 0.85rem;
      color: var(--gray-600);
    }

    /* Adverse Event Reporting */
    .adverse-section {
      background: #fef2f2;
      border: 2px solid #fecaca;
      border-radius: 16px;
      padding: 2rem;
      margin-bottom: 3rem;
    }
    .adverse-section h2 { color: #991b1b; }
    .adverse-timeline {
      display: grid;
      grid-template-columns: repeat(4, 1fr);
      gap: 1rem;
      margin: 1.5rem 0;
    }
    @media (max-width: 768px) { .adverse-timeline { grid-template-columns: repeat(2, 1fr); } }
    .adverse-item {
      background: white;
      border-radius: 10px;
      padding: 1rem;
      text-align: center;
    }
    .adverse-hours {
      font-size: 1.5rem;
      font-weight: 800;
      color: #dc2626;
    }
    .adverse-label {
      font-size: 0.75rem;
      color: var(--gray-600);
      margin-top: 0.25rem;
    }

    /* Sample Clause */
    .sample-clause {
      background: var(--gray-50);
      border-left: 4px solid var(--research);
      padding: 1rem;
      font-size: 0.85rem;
      font-style: italic;
      color: var(--gray-600);
      border-radius: 0 8px 8px 0;
      margin-top: 1rem;
    }

    /* Generator CTA */
    .generator-cta {
      background: linear-gradient(135deg, var(--research) 0%, #5b21b6 100%);
      border-radius: 16px;
      padding: 2.5rem;
      text-align: center;
      margin-bottom: 3rem;
    }
    .generator-cta h2 {
      font-size: 1.75rem;
      font-weight: 800;
      color: white;
      margin-bottom: 0.5rem;
    }
    .generator-cta p {
      color: rgba(255,255,255,0.9);
      margin-bottom: 1.5rem;
    }
    .generator-cta .btn {
      background: white;
      color: var(--research);
      padding: 1rem 2rem;
      border-radius: 10px;
      font-weight: 700;
      font-size: 1rem;
      text-decoration: none;
      display: inline-block;
      transition: all 0.2s;
    }
    .generator-cta .btn:hover {
      transform: translateY(-2px);
      box-shadow: 0 10px 20px rgba(0,0,0,0.2);
    }

    /* Attorney Disclaimer */
    .attorney-disclaimer {
      background: #f0f9ff;
      border: 2px solid #0ea5e9;
      border-radius: 12px;
      padding: 1.5rem;
      text-align: center;
      margin-bottom: 3rem;
    }
    .attorney-disclaimer h4 {
      color: #0369a1;
      font-size: 1rem;
      font-weight: 700;
      margin-bottom: 0.5rem;
    }
    .attorney-disclaimer p {
      color: #0c4a6e;
      font-size: 0.9rem;
    }
    .attorney-disclaimer a {
      color: #0369a1;
      font-weight: 600;
    }

    /* Footer */
    .footer {
      background: var(--dark);
      padding: 3rem 2rem;
      color: var(--gray-300);
    }
    .footer-inner {
      max-width: 1200px;
      margin: 0 auto;
      display: flex;
      justify-content: space-between;
      align-items: center;
    }
    .footer-links { display: flex; gap: 2rem; }
    .footer-links a {
      color: var(--gray-300);
      text-decoration: none;
      font-size: 0.9rem;
    }
    .footer-links a:hover { color: white; }

    @media (max-width: 768px) {
      .hero h1 { font-size: 2rem; }
      .footer-inner { flex-direction: column; gap: 1rem; text-align: center; }
      .hub-subnav-tabs { display: none; }
    }
  </style>
</head>
<body>

<!-- Header -->
<header class="site-header">
    <div class="header-content">
        <a href="/" class="site-logo">Terms.Law</a>
        <nav class="site-nav">
            <a href="/NDA/" class="nav-link">NDA Studio</a>
            <a href="/NDA/industry-packs/" class="nav-link">Industry Packs</a>
            <a href="/NDA/clause-library/" class="nav-link">Clause Library</a>
            <a href="mailto:owner@terms.law" class="nav-link nav-cta">Contact</a>
        </nav>
    </div>
</header>

<!-- Hub Sub-Navigation -->
<nav class="hub-subnav">
  <div class="hub-subnav-content">
    <a href="./" class="hub-subnav-title">&#9764;&#65039; Healthcare NDA Pack</a>
    <div class="hub-subnav-tabs">
      <a href="./" class="hub-tab">Overview</a>
      <a href="hipaa-compliant-nda.html" class="hub-tab">HIPAA NDA</a>
      <a href="medical-research-nda.html" class="hub-tab active">Research</a>
      <a href="pharma-partnership-nda.html" class="hub-tab">Pharma</a>
      <a href="telemedicine-nda.html" class="hub-tab">Telemedicine</a>
      <a href="patient-data-nda.html" class="hub-tab">Patient Data</a>
      <a href="compliance-checklist.html" class="hub-tab">Checklist</a>
    </div>
  </div>
</nav>

<!-- Hero -->
<section class="hero">
  <div class="hero-inner">
    <div class="hero-badge">
      <span>&#128300;</span> Clinical Trials & Research
    </div>
    <h1>Medical Research NDA</h1>
    <p class="hero-sub">
      Specialized NDA provisions for clinical trials, research collaborations, and academic partnerships. Includes IRB considerations, publication rights, and FDA submission requirements.
    </p>
  </div>
</section>

<!-- Main Content -->
<div class="main-content">

  <!-- Research Types -->
  <div class="research-types">
    <div class="research-type-card">
      <div class="research-type-icon">&#129514;</div>
      <h3>Clinical Trials</h3>
      <p>Phase I-IV trials, investigator-sponsored studies, and multi-site research protocols.</p>
    </div>
    <div class="research-type-card">
      <div class="research-type-icon">&#127891;</div>
      <h3>Academic Collaborations</h3>
      <p>University partnerships, sponsored research, and joint research agreements.</p>
    </div>
    <div class="research-type-card">
      <div class="research-type-icon">&#128202;</div>
      <h3>Data Sharing</h3>
      <p>Registry access, biobank partnerships, and secondary research use agreements.</p>
    </div>
  </div>

  <!-- IRB Considerations -->
  <section class="irb-section">
    <h2>&#128203; IRB Considerations</h2>
    <p>Research NDAs involving human subjects must address Institutional Review Board requirements and protections.</p>

    <div class="irb-considerations">
      <div class="irb-item">
        <div class="irb-item-icon">&#128270;</div>
        <div>
          <h4>Protocol Alignment</h4>
          <p>NDA scope must align with IRB-approved protocol and consent forms.</p>
        </div>
      </div>
      <div class="irb-item">
        <div class="irb-item-icon">&#128100;</div>
        <div>
          <h4>Subject Protections</h4>
          <p>Confidentiality provisions must meet or exceed consent form promises.</p>
        </div>
      </div>
      <div class="irb-item">
        <div class="irb-item-icon">&#128196;</div>
        <div>
          <h4>Modification Procedures</h4>
          <p>Changes to data sharing may require IRB amendment approval.</p>
        </div>
      </div>
      <div class="irb-item">
        <div class="irb-item-icon">&#128274;</div>
        <div>
          <h4>Retention Requirements</h4>
          <p>Data retention must comply with IRB and regulatory requirements.</p>
        </div>
      </div>
    </div>

    <div class="sample-clause">
      The Receiving Party acknowledges that the research data disclosed hereunder was collected pursuant to research protocols approved by [Institution]'s Institutional Review Board (IRB). Receiving Party agrees to use such data solely in accordance with the approved protocol and to immediately notify Disclosing Party of any proposed use that may require additional IRB approval.
    </div>
  </section>

  <!-- De-identification -->
  <section class="deid-section">
    <h2>&#128274; Data De-identification Requirements</h2>
    <p>HIPAA provides two methods for de-identifying patient data for research purposes.</p>

    <div class="deid-methods">
      <div class="deid-method preferred">
        <h4>Safe Harbor Method</h4>
        <span class="tag tag-preferred">Preferred for Research</span>
        <p>Remove all 18 HIPAA-specified identifiers. Clear, objective standard.</p>
        <ul class="identifiers-list">
          <li>Names, addresses, dates (except year)</li>
          <li>Phone, fax, email, SSN, MRN</li>
          <li>Health plan numbers, account numbers</li>
          <li>Vehicle identifiers, device IDs</li>
          <li>URLs, IP addresses, biometrics</li>
          <li>Full-face photos, unique codes</li>
        </ul>
      </div>
      <div class="deid-method">
        <h4>Expert Determination</h4>
        <span class="tag tag-alternative">Alternative</span>
        <p>Statistical expert certifies re-identification risk is very small.</p>
        <ul class="identifiers-list">
          <li>More flexible than Safe Harbor</li>
          <li>Allows retention of some identifiers</li>
          <li>Requires qualified statistical expert</li>
          <li>Must document methods used</li>
          <li>Annual re-certification recommended</li>
        </ul>
      </div>
    </div>

    <div class="sample-clause">
      Prior to disclosure, Disclosing Party shall de-identify all research data in accordance with 45 CFR 164.514(b)(2) (Safe Harbor method) by removing all eighteen (18) categories of identifiers specified therein. Receiving Party shall not attempt to re-identify any individual from the de-identified data or link such data with other data sources.
    </div>
  </section>

  <!-- Publication Rights -->
  <section class="publication-section">
    <h2>&#128218; Publication Rights & Timing</h2>
    <p>Balancing open science with intellectual property protection and sponsor interests.</p>

    <div class="publication-timeline">
      <div class="timeline-point">
        <div class="timeline-dot">1</div>
        <div class="timeline-label">Manuscript submitted for review</div>
      </div>
      <div class="timeline-point">
        <div class="timeline-dot">30d</div>
        <div class="timeline-label">Sponsor review period</div>
      </div>
      <div class="timeline-point">
        <div class="timeline-dot">60d</div>
        <div class="timeline-label">Patent filing delay (if needed)</div>
      </div>
      <div class="timeline-point">
        <div class="timeline-dot">90d</div>
        <div class="timeline-label">Maximum delay typical</div>
      </div>
    </div>

    <p style="font-size: 0.9rem; color: var(--gray-600); margin-bottom: 1rem;"><strong>Key negotiation points:</strong></p>
    <ul style="font-size: 0.9rem; color: var(--gray-600); margin-left: 1.5rem; margin-bottom: 1rem;">
      <li>Right to publish vs. discretionary approval</li>
      <li>Removal of confidential information only vs. substantive edits</li>
      <li>Patent filing delay rights and duration</li>
      <li>Multi-site coordination requirements</li>
      <li>Acknowledgment and authorship requirements</li>
    </ul>

    <div class="sample-clause">
      Investigator shall have the right to publish research results, subject to a thirty (30) day review period during which Sponsor may identify Confidential Information for removal. Publication may be delayed an additional sixty (60) days if necessary to file patent applications. In no event shall total delay exceed ninety (90) days from manuscript submission.
    </div>
  </section>

  <!-- Adverse Event Reporting -->
  <section class="adverse-section">
    <h2>&#128680; Adverse Event Reporting Obligations</h2>
    <p>Research NDAs must address safety reporting requirements that may supersede confidentiality.</p>

    <div class="adverse-timeline">
      <div class="adverse-item">
        <div class="adverse-hours">24h</div>
        <div class="adverse-label">Fatal/Life-threatening events to sponsor</div>
      </div>
      <div class="adverse-item">
        <div class="adverse-hours">7d</div>
        <div class="adverse-label">IND Safety Reports to FDA</div>
      </div>
      <div class="adverse-item">
        <div class="adverse-hours">15d</div>
        <div class="adverse-label">Serious unexpected events</div>
      </div>
      <div class="adverse-item">
        <div class="adverse-hours">Annual</div>
        <div class="adverse-label">Safety summary reports</div>
      </div>
    </div>

    <div class="sample-clause">
      Notwithstanding any confidentiality obligations herein, Investigator shall immediately report to Sponsor any serious adverse event (as defined in 21 CFR 312.32) occurring during the study, and Sponsor shall have the right to report such events to FDA and other regulatory authorities as required by law. Such safety reporting shall not constitute a breach of this Agreement.
    </div>
  </section>

  <!-- FDA Submission Rights -->
  <section class="fda-section" id="fda">
    <h2>&#127981; FDA Submission Rights</h2>
    <p>Clinical research data is often destined for regulatory submissions. NDAs should address who has submission rights.</p>

    <div class="fda-rights">
      <div class="fda-right">
        <h4>Sponsor Right to Reference</h4>
        <p>Sponsor may reference and submit all trial data in regulatory filings worldwide.</p>
      </div>
      <div class="fda-right">
        <h4>Data Exclusivity</h4>
        <p>Address whether data can be used to support generic or biosimilar applications.</p>
      </div>
      <div class="fda-right">
        <h4>Cross-Reference Letters</h4>
        <p>Right to provide cross-reference authorization to other parties.</p>
      </div>
      <div class="fda-right">
        <h4>21 CFR Part 11 Compliance</h4>
        <p>Electronic records and signatures must meet FDA requirements.</p>
      </div>
    </div>

    <div class="sample-clause">
      Investigator hereby grants to Sponsor the irrevocable right to reference, use, and submit all study data, including raw data and source documents, in any regulatory filing worldwide. This includes the right to authorize third parties to cross-reference such data. Sponsor shall own all regulatory rights in the study data.
    </div>
  </section>

  <!-- Generator CTA -->
  <section class="generator-cta">
    <h2>Generate Your Medical Research NDA</h2>
    <p>Customize provisions for your specific research collaboration, clinical trial, or academic partnership.</p>
    <a href="/NDA/generator.html?scenario=medical-research" class="btn">Generate Research NDA &#8594;</a>
  </section>

  <!-- Attorney Disclaimer -->
  <div class="attorney-disclaimer">
    <h4>&#9878;&#65039; Consult a Research Attorney</h4>
    <p>Clinical research agreements involve complex regulatory requirements including FDA, OHRP, and institutional policies. We strongly recommend having experienced research counsel review any agreement involving human subjects research. <a href="mailto:owner@terms.law">Request a consultation</a>.</p>
  </div>

</div>

<!-- Footer -->
<footer class="footer">
  <div class="footer-inner">
    <div>&copy; 2025 Terms.Law &mdash; Sergei Tokmakov, Esq. &bull; CA Bar #279869</div>
    <div class="footer-links">
      <a href="/NDA/">NDA Studio</a>
      <a href="./">Healthcare Pack</a>
      <a href="mailto:owner@terms.law">Contact</a>
    </div>
  </div>
</footer>

<!-- Chat Widget -->
<script src="/chat-widget/chat-widget.js"></script>

</body>
</html>
